Source comparison
Sermorelin vs Exogenous Growth Hormone — Receptor Preservation
The critical distinction between sermorelin and recombinant human growth hormone (rhGH) is feedback loop preservation. Exogenous GH. Synthetic somatropin injected subcutaneously. Floods GH receptors in peripheral tissues (liver, muscle, adipose) with supraphys
This comparison does not assign a generated winner or score.
- The critical distinction between sermorelin and recombinant human growth hormone (rhGH) is feedback loop preservation. Exogenous GH. Synthetic somatropin injected subcutaneously. Floods GH receptors in peripheral tissues (liver, muscle, adipose) with supraphysiologic concentrations that bypass the pituitary entirely. This suppresses endogenous GH production through negative feedback at the hypothalamus, downregulates GH receptors over time (reducing tissue sensitivity), and disrupts the natural pulse pattern that coordinates with cortisol, insulin, and thyroid hormones. Women who use exogenous GH for extended periods often develop insulin resistance, joint swelling, and rebound somatopause (worsened endogenous GH suppression) when they stop. The body has adapted to external supply by shutting down internal production.
- Sermorelin avoids this cascade entirely. Because it stimulates the pituitary rather than replacing its output, endogenous feedback mechanisms remain intact. When circulating GH and IGF-1 reach adequate levels, somatostatin naturally inhibits further release. Preventing supraphysiologic spikes. When GH drops below threshold, the pituitary remains responsive to the next sermorelin dose, maintaining physiologic pulsatility rather than pharmacologic flooding. A Phase 2 trial conducted at the University of Washington measured pituitary responsiveness in postmenopausal women after 6 months of nightly sermorelin dosing. GHRH receptor density and peak GH output remained stable, confirming no desensitization or downregulation occurred. This is why sermorelin can be used long-term without the receptor burnout seen with exogenous GH protocols.
- For women 45-55 perimenopause researching sermorelin, this translates to a sustainable intervention rather than a short-term metabolic boost. The peptide doesn't shut down what's left of your endogenous GH production. It amplifies it. Women concerned about dependency should understand that sermorelin preserves the axis it's designed to support, making it physiologically safer for extended use than rhGH replacement.